All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Mindrank Ltd. has received clearance of its IND application by the FDA for MDR-001, a small-molecule glucagon-like peptide 1 (GLP-1) receptor agonist, which was discovered using the company’s proprietary artificial intelligence (AI) platform, Molecule Pro.
Protego Biopharma Inc. and Scripps Research Institute have identified serine/threonine kinase/endoribonuclease IRE1 (ERN1) activators reported to be useful for the treatment of diabetes, myocardial infarction, nonalcoholic fatty liver disease (NAFLD), Parkinson's disease, retinal degeneration, atherosclerosis, Gaucher disease and Alzheimer's disease, among others.
Sosei Heptares and Eli Lilly and Co. have signed a potential $731 million deal to discover, develop and commercialize small molecules that modulate G protein-coupled receptor (GPCR) targets associated with diabetes and metabolic diseases.
Hepcidin deficiency in hereditary hemochromatosis (HH) leads to increased absorption of dietary iron and thus iron overload. Rusfertide is a hepcidin mimetic peptide that has shown efficacy at reducing the need for therapeutic maintenance phlebotomy in patients with HH. Researchers aimed to evaluate the benefits of cotreatment with a hepcidin mimetic peptide plus the rusfertide analogue PN-23114 (Protagonist Therapeutics Inc.) at 7.5 mg/kg t.i.w. and phlebotomy in a murine model of HH.
Genprex Inc. has entered into a license agreement with the University of Pittsburgh designed to strengthen its diabetes program. The agreement grants Genprex a worldwide, exclusive license to certain patent applications and related technology and a worldwide, nonexclusive license to use certain related know-how, all related to modulating autoimmunity in type 1 diabetes by using gene therapy.
The farnesoid X receptor (FXR), a bile acid receptor, plays a direct role regulating innate immune cells in the gut, and treating mice with an FXR agonist improved symptoms of inflammatory bowel disease (IBD). The findings provide a link between diet and innate immunity, and could lead to better ways to treat IBD. “The intestine is a major target for inflammation and inflammatory disease, particularly in the modern Western culture, where high-fat diets are becoming very prevalent,” Ronald Evans told BioWorld.
Wave Life Sciences Ltd. and GSK plc have entered into a strategic collaboration to advance oligonucleotide therapeutics, including Wave's preclinical RNA editing program targeting α1-antitrypsin deficiency (AATD), WVE-006. The discovery collaboration has an initial 4-year research term. The first part of the arrangement is a discovery collaboration that enables GSK to advance up to eight programs and Wave to advance up to three programs, leveraging Wave's PRISM oligonucleotide platform and GSK's expertise in genetics and genomics.
Jiangsu Chia Tai Tianqing Pharmaceutical Group Co. Ltd. has presented solute carrier family 22 member 12 (SLC22A12) inhibitors reported to be useful for the treatment of gout and hyperuricemia.
Liver damage arrests growth mediated by the somatotroph axis, which prevents liver cell death and inflammation, but increases fibrosis in nonalcoholic fatty liver disease (NAFLD). The explanation for this effect could lie in the relationship between the activating transcription factor 3 (ATF-3) and insulin-like growth factor 1 (IGF-1), according to a study from the University of California at Berkeley.
The positively charged nanoparticle polyamidoamine generation 3 (P-G3) can be specifically targeted to either visceral or subcutaneous fat, and affects both types of fat in different ways, researchers from Columbia University reported in two papers recently published.
RSS
